Document:

Exhibit 10.4

 

FTD COMPANIES, INC.

  RESTRICTED STOCK UNIT ISSUANCE AGREEMENT

 

RECITALS

 

A.                                    The Board has adopted the FTD Companies, Inc. Amended and Restated 2013 Incentive Compensation Plan (the “Plan”), for the purpose of retaining the services of selected Employees and consultants, non-employee Board members and other independent advisors who provide services to the Corporation (or any Parent or Subsidiary).

 

B.                                    The Participant is a member of the Board, and this Agreement is executed pursuant to, and is intended to carry out the purposes of, the Plan in providing a meaningful incentive for the Participant to continue to serve as a Board member.

 

C.                                    All capitalized terms in this Agreement shall have the meaning assigned to them in the Plan unless otherwise defined in this Agreement, including on Appendix A attached hereto.

 

NOW, THEREFORE, it is hereby agreed as follows:

 

1.              Grant of Restricted Stock Units.  The Corporation has awarded to the Participant, as of the Award Date, Restricted Stock Units under the Plan. Each Restricted Stock Unit represents the right to receive one share of Common Stock on the applicable issuance date following the vesting of that Restricted Stock Unit. The number of shares of Common Stock subject to the awarded Restricted Stock Units, the applicable vesting schedule for the Restricted Stock Units, the dates on which those vested Restricted Stock Units shall become payable to the Participant and the remaining terms and conditions governing the award (the “Award”) shall be as set forth in this Agreement.

 

AWARD SUMMARY

 

	
Award Date:
    	
 
    	
<Grant Date>
    
	
 
    	
 
    	
 
    
	
Number of Restricted Stock Units Subject to Award:
    	
 
    	
<Shares Granted> Restricted Stock Units
    
	
 
    	
 
    	
 
    
	
Vesting Schedule:
    	
 
    	
The Restricted Stock Units shall vest in full upon   the Participant’s continued service as a Board member through                           (the “Vesting Date”). The Restricted Stock Units shall also be subject to   accelerated vesting in whole or in part in accordance with the provisions of   Paragraphs 4 and 6 of this Agreement.
    

 

 

	
Issuance Schedule:
    	
 
    	
Each Restricted Stock Unit in which the Participant   vests in accordance with the foregoing vesting provisions shall be issued in   compliance with Section 409A of the Code. Accordingly, the Restricted   Stock Units in which the Participant vests on the Vesting Date shall be   settled in shares of Common Stock on that date or as soon thereafter as   administratively practicable, but in no event later than 30 days after the   Vesting Date. Any Restricted Stock Units or amounts which vest pursuant to   the acceleration provision of either Paragraph 4 or Paragraph 6 of this   Agreement shall be settled in shares of Common Stock on the earlier of:
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
(i)  the Vesting   Date or as soon thereafter as administratively practicable, but in no event   later than 30 days after the Vesting Date;

 

(ii)  the date of   the Participant’s Separation from Service, or as soon thereafter as   administratively practicable, but in no event later than 30 days after the   Participant’s Separation from Service; and

 

(iii)  if the   Restricted Stock Units vest upon a Change in Control, the effective date of a   Change in Control or as soon as administratively practicable thereafter, but   in no event later than three (3) business days following such effective   date, if that transaction also qualifies as a change in control event under   Code Section 409A and the Treasury Regulations thereunder (in the   absence of such a qualifying change in control, the distribution shall not be   made until the date or dates on which those amounts are otherwise to be   distributed under (i) or (ii) above).
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
The date on which the Restricted Stock Units are to   be settled in accordance with the foregoing is hereby designated the   “Issuance Date.”
    

 

2.              Limited Transferability.  Prior to the vesting of the Restricted Stock Units and actual receipt of the underlying shares of Common Stock paid hereunder, the Participant may not transfer any interest in the Award or the underlying shares of Common Stock. Any Restricted Stock Units that vest hereunder but which otherwise remain unpaid at the time of the Participant’s death may be transferred pursuant to the provisions of the Participant’s will or the laws of inheritance or to the Participant’s designated beneficiary or beneficiaries of this Award. The Participant may also direct the Corporation to re-issue the stock certificates for any shares of Common Stock that were issued under the Award during his or her lifetime to one or more designated family members or a trust established for the Participant and/or his or her family members. The Participant may make such a beneficiary designation or certificate directive at any time by filing the appropriate form with the Plan Administrator or its designee.

 

3.              Cessation of Service.  Except as otherwise provided in Paragraphs 4 and 6 below, should the Participant cease to serve as a Board member for any reason prior to vesting in the Restricted Stock Units subject to this Award, then the awarded Restricted Stock Units will be immediately cancelled with respect to those unvested Restricted Stock Units, and the Participant shall thereupon cease to have any right or entitlement to receive any shares of Common Stock under those cancelled Restricted Stock Units.

 

2

 

4.              Accelerated Vesting.

 

(a)                                 Should the Participant cease to serve as a Board member by reason of death or Permanent Disability, then all of the Restricted Stock Units at the time subject to this Award shall immediately vest in full.

 

(b)                                 Should the Participant voluntarily resign from the Board under circumstances that would not otherwise trigger the vesting acceleration provisions of Paragraph 4(a) or Paragraph 6, then the Participant shall immediately vest in the number of Restricted Stock Units in which the Participant would have been vested at the time of such resignation had the Restricted Stock Units subject to this Award vested in a series of successive equal monthly installments over the duration of the Vesting Schedule.

 

(c)                                  Any Restricted Stock Units which become vested pursuant to Paragraph 4 by reason of the Participant’s cessation of Service shall be distributed to the Participant pursuant to Paragraph 1.

 

5.              Stockholder Rights and Dividend Equivalents

 

(a)                                 The holder of this Award shall not have any stockholder rights, including voting or dividend rights, with respect to the Restricted Stock Units subject to this Award until the Participant becomes the record holder of the underlying shares of Common Stock following their actual issuance.

 

(b)                                 Notwithstanding the foregoing, should any dividend or other distribution, whether regular or extraordinary, payable in cash or other property (other than shares of Common Stock) be declared and paid on the outstanding Common Stock while one or more Restricted Stock Units remain subject to this Award (i.e., shares are not otherwise issued and outstanding for purposes of entitlement to the dividend or distribution), then the following provisions shall govern the Participant’s interest in that dividend or distribution:

 

(i)                                     If the dividend is a regularly-scheduled cash dividend on the Common Stock, then the Participant shall be entitled to a current cash distribution from the Corporation equal to the cash dividend the Participant would have received with respect to the Restricted Stock Units at the time subject to this Award had the underlying shares of Common Stock actually been issued and outstanding and entitled to that cash dividend. Each cash dividend equivalent payment under this subparagraph (i) shall be paid within five (5) business days following the payment of the actual cash dividend on the outstanding Common Stock.

 

(ii)                                  For any other dividend or distribution, a special book account shall be established for the Participant and credited with a phantom dividend equivalent to the actual dividend or distribution which would have been paid on the underlying shares of Common Stock at the time subject to this Award had they been issued and outstanding and entitled to that dividend or distribution.  As the Restricted Stock Units subsequently vest hereunder, the phantom dividend equivalents so credited to those Restricted Stock Units in the book account shall also vest, and those vested dividend equivalents shall be distributed to the Participant (in the same

 

3

 

                                                form the actual dividend or distribution was paid to the holders of the Common Stock entitled to that dividend or distribution) concurrently with the issuance of the vested Restricted Stock Units to which those phantom dividend equivalents relate.  In no event, however, shall any such phantom dividend equivalents vest or become distributable unless the Restricted Stock Units to which they relate vest in accordance with the terms of this Agreement.

 

6.              Change in Control.

 

(a)                                 Any Restricted Stock Units subject to this Award at the time of a Change in Control may be assumed, converted or replaced by the successor entity (or parent thereof) or otherwise continued in full force and effect or may be replaced with a cash program of the successor entity (or parent thereof) on terms as required under the Plan (a “Replacement Award”).  In the event of such Replacement Award, no accelerated vesting of the Restricted Stock Units (the “Replaced Award”) shall occur at the time of the Change in Control.  Notwithstanding the foregoing, no such cash program shall be established for the Replaced Award to the extent such program would otherwise be deemed to constitute a deferred compensation arrangement subject to the requirements of Code Section 409A and the Treasury Regulations thereunder.

 

(b)                                 For purposes of this Agreement, a “Replacement Award” means an award: (i) of the same type (e.g., time-based restricted stock units) as the Replaced Award; (ii) that has a value at least equal to the value of the Replaced Award; (iii) that relates to publicly traded equity securities of the Corporation or its successor in the Change in Control or another entity that is affiliated with the Corporation or its successor following the Change in Control; (iv) if the Participant holding the Replaced Award is subject to U.S. federal income tax under the Code, the tax consequences of which to such Participant under the Code are not less favorable to such Participant than the tax consequences of the Replaced Award; and (v) the other terms and conditions of which are not less favorable to the Participant holding the Replaced Award than the terms and conditions of the Replaced Award (including the provisions that would apply in the event of a subsequent Change in Control).  A Replacement Award may be granted only to the extent it does not result in the Replaced Award or Replacement Award failing to comply with or be exempt from Section 409A of the Code.  Without limiting the generality of the foregoing, the Replacement Award may take the form of a continuation of the Replaced Award if the requirements of the two preceding sentences are satisfied.  The determination of whether the conditions of this Paragraph 6(b) are satisfied will be made by the Plan Administrator, as constituted immediately before the Change in Control, in its sole discretion.

 

(c)                                  In the event of a Replacement Award, the Replaced Award shall be adjusted immediately after the consummation of the Change in Control so as to apply to the number and class of securities into which the shares of Common Stock subject to the Replaced Award immediately prior to the Change in Control would have been converted in consummation of that Change in Control had those shares of Common Stock actually been issued and outstanding at that time. To the extent the actual holders of the outstanding Common Stock receive cash consideration for their Common Stock in consummation of the Change in Control, the successor entity (or parent thereof) may, in connection with the Replacement Award at that time, but subject to the Plan Administrator’s approval prior to the Change in Control, substitute one or more shares of its own common stock with a fair market value equivalent to the cash consideration paid per share of Common Stock in the Change in Control transaction, provided the substituted common stock is readily tradable on an established U.S. securities exchange.

 

(d)                                 Any Replacement Award shall be subject to accelerated vesting in accordance with the following provisions:  If an Involuntary Termination of the Participant’s Service

 

4

 

occurs within twelve (12) months after the Change in Control event, then the Participant shall immediately vest in the Replacement Award.  In the event of a replacement cash program under Paragraph 6(a), the foregoing provisions shall be applied to the proceeds of such replacement program attributable to the Replaced Award had the Award been assumed or otherwise continued in effect.

 

(e)                                  If no Replacement Award is provided, then the Restricted Stock Units shall vest immediately prior to the closing of the Change in Control.  The vested Restricted Stock Units shall be converted into the right to receive for each such Restricted Stock Unit the same consideration per share of Common Stock payable to the other stockholders of the Corporation in consummation of that Change in Control.

 

(f)                                   This Agreement shall not in any way affect the right of the Corporation to adjust, reclassify, reorganize or otherwise change its capital or business structure or to merge, consolidate, dissolve, liquidate or sell or transfer all or any part of its business or assets.  Additionally, if a Replacement Award is provided, notwithstanding anything in this Agreement to the contrary, any outstanding Restricted Stock Units that at the time of the Change in Control are not subject to a “substantial risk of forfeiture” (within the meaning of Section 409A of the Code) will be deemed to be vested at the time of such Change in Control.

 

7.              Adjustment in Shares.  The total number and/or class of securities issuable pursuant to this Award and the other terms of this Award shall be subject to adjustment upon certain corporate events as set forth in Article One, Section V(F) of the Plan.  The adjustments shall be made in such manner as the Plan Administrator deems appropriate, and those adjustments shall be final, binding and conclusive.

 

8.              Issuance of Shares of Common Stock.

 

(a)                                 On the applicable Issuance Date for the Restricted Stock Units which vest in accordance with the provisions of this Agreement, the Corporation shall issue to or on behalf of the Participant a certificate (which may be in electronic form) or provide for book entry for the shares of Common Stock to be issued on such date and shall concurrently distribute to the Participant any accrued phantom dividend equivalents with respect to those vested Restricted Stock Units.

 

(b)                                 Except as otherwise provided in Paragraph 6, the settlement of all Restricted Stock Units which vest under the Award shall be made solely in shares of Common Stock.  No fractional share of Common Stock shall be issued pursuant to this Award, and any fractional share resulting from any calculation made in accordance with the terms of this Agreement shall be rounded down to the next whole share of Common Stock.

 

9.              Compliance with Laws and Regulations. The issuance of shares of Common Stock pursuant to the Award shall be subject to compliance by the Corporation and the Participant with all applicable requirements of law relating thereto and with all applicable regulations of the Stock Exchange on which the Common Stock is listed for trading at the time of such issuance.

 

10.       Notices.  Any notice required to be given or delivered to the Corporation under the terms of this Agreement shall be in writing and addressed to the Corporation at its principal corporate offices, and directed to the attention of Stock Plan Administrator.  Any notice required to be given or delivered to the Participant shall be in writing and addressed to the Participant at the most current address then indicated for the Participant on the Corporation’s records or delivered electronically to the

 

5

 

Participant through the Corporation’s electronic mail system.  All notices shall be deemed effective upon personal delivery or delivery through the Corporation’s electronic mail system or upon deposit in the U.S. mail, postage prepaid and properly addressed to the party to be notified.

 

11.       Governing Law.  The interpretation, performance and enforcement of this Agreement shall be governed by the laws of the State of Delaware without resort to that state’s conflict-of-laws rules.

 

12.       Successors and Assigns.  Except to the extent otherwise provided in this Agreement, the provisions of this Agreement shall inure to the benefit of, and be binding upon, the Corporation and its successors and assigns and the Participant, the Participant’s assigns, the legal representatives, heirs and legatees of the Participant’s estate and any beneficiaries of the Award designated by the Participant.

 

13.       Construction.  This Agreement and the Award evidenced hereby are made and granted pursuant to the Plan and are in all respects limited by and subject to the terms of the Plan.  All decisions of the Plan Administrator with respect to any question or issue arising under the Plan or this Agreement shall be conclusive and binding on all persons having an interest in the Award.

 

14.       No Impairment of Rights.  Nothing in this Agreement shall in any way affect the right of the Corporation to adjust, reclassify, reorganize or otherwise make changes in its capital or business structure or to merge, consolidate, dissolve, liquidate or sell or transfer all or any part of its business or assets.  In addition, this Agreement shall not in any way be construed or interpreted so as to affect adversely or otherwise impair the right of the Corporation or the stockholders to remove the Participant from the Board at any time in accordance with the provisions of applicable law.

 

15.       Code Section 409A.  It is the intention of the parties that the provisions of this Agreement comply with the requirements of Section 409A of the Code and, this Agreement shall be interpreted and applied in accordance with such intent.

 

IN WITNESS WHEREOF, the parties have executed this Agreement on the day and year first indicated above.

 

	
 
    	
FTD COMPANIES, INC.
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
Title:
    	
 
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
PARTICIPANT
    
	
 
    	
 
    
	
 
    	
Name: <Participant   Name>
    
	
 
    	
 
    
	
 
    	
Signature:   <Electronic Signature>
    

 

6

 

APPENDIX A

 

The following definitions shall be in effect under the Agreement:

 

A.            Agreement shall mean this Restricted Stock Unit Issuance Agreement.

 

B.            Award shall mean the award of restricted stock units made to the Participant pursuant to the terms of this Agreement.

 

C.            Award Date shall mean the date the restricted stock units are awarded to the Participant pursuant to the Agreement and shall be the date indicated in Paragraph 1 of the Agreement.

 

D.            Involuntary Termination shall mean the termination of the Participant’s Service that occurs by reason of the Participant’s involuntary termination of Service by the Corporation for reasons other than Cause.

 

E.             Participant shall mean the person to whom the Award is made pursuant to the Agreement.

 

F.              Plan Administrator shall mean either the Board or a committee of the Board acting in its capacity as administrator of the Plan.

 

G.            Permanent Disability shall mean the inability of the Participant to perform his or her usual duties as a member of the Board by reason of any medically determinable physical or mental impairment which is expected to result in death or has lasted or can be expected to last for a continuous period of twelve (12) months or more.

 

H.           Separation from Service shall mean the Participant’s cessation of Service as determined in accordance with the applicable standards of the Treasury Regulations issued under Code Section 409A.EX-10.1

 Exhibit 10.1 

CONSULTING AGREEMENT 

THIS CONSULTING AGREEMENT (the “Agreement”) is entered into as of August 5, 2015 by and between Epizyme, Inc. (the
“Company”), and Robert J. Gould (together, the “Parties”). 
 WHEREAS, concurrent with the execution of this Agreement,
Dr. Gould has delivered to the Company his resignation from his positions as President and Chief Executive Officer of the Company, effective September 10, 2015; 

WHEREAS, the Company desires to engage Dr. Gould as a consultant to the Company following the effectiveness of his resignation; and 

WHEREAS, Dr. Gould has agreed to provide such services pursuant to the terms and conditions set forth in this Agreement; 

NOW, THEREFORE in consideration of the mutual covenants and promises contained herein, and other good and valuable consideration, the receipt
and sufficiency of which is hereby acknowledged by the parties hereto, the parties agree as follows: 
 1. Services To Be
Performed. Commencing upon September 10, 2015, (the “Effective Date”) and continuing for the duration of the Consultation Period (as defined below), Dr. Gould agrees to perform such consulting, advisory and related
services to and for the Company as may be reasonably requested from time to time by the Company (the “Services”). The Consultant agrees to devote up to (i) 1.5 days per week to the performance of the Services for the period beginning
on the Effective Date and ending on December 31, 2015 and (ii) 0.5 days per week to the performance of the Services for the balance of the Consultation Period. Dr. Gould agrees to use his best efforts in the performance of the
Services and agrees to cooperate with the Company’s personnel, not to interfere with the conduct of the Company’s business, and to observe all Company rules, regulations and security requirements with respect to the safety and safeguarding
of persons and property.  
 2. Term. This Agreement shall commence upon the Effective Date and shall continue until
the first anniversary of the Effective Date (such period, as it may be extended upon mutual agreement of the parties, being referred to as the “Consultation Period”), unless sooner terminated in accordance with the provisions of
Section 5. 
 3. Consulting Benefits. The Company will provide Dr. Gould with the payments and benefits set
forth below (the “Consulting Benefits”).  
 a. Fees. The Company will pay Dr. Gould during the Consultation
Period fees at a rate of $41,666 per month (the “Fees”), which Fees shall be (i) reduced by all applicable taxes and withholdings as determined by the Company in its sole discretion, (ii) paid to Dr. Gould in accordance with
the Company’s regular payroll practices and (iii) subject to a pro rata adjustment for any partial calendar month. Notwithstanding the foregoing, the Company shall not pay any Fees to Dr. Gould earlier than the date eight
(8) days after Dr. Gould’s timely execution, return and non-revocation of the Release of Claims attached hereto as Exhibit A (the “Release of Claims”). 

 b. Bonus. At the time that the Company regularly pays out management bonuses for 2015, the
Company shall pay to Dr. Gould a bonus payment of $175,000. Such bonus payment shall be paid to Dr. Gould in a lump sum payment, less all applicable taxes and withholdings as determined by the Company in its sole discretion. Upon the
Effective Date, Dr. Gould shall cease to be eligible for any bonus under his offer letter with the Company dated April 13, 2013 or otherwise. Notwithstanding the foregoing, the Company shall not pay any bonus to Dr. Gould under this
Section 3(b) earlier than the date eight (8) days after Dr. Gould’s timely execution, return and non-revocation of the Release of Claims. 

c. COBRA. Dr. Gould’s current coverage under the Company’s group medical insurance plan will end on the Effective Date.
Provided that Dr. Gould elects to continue receiving group medical insurance pursuant to the federal “COBRA” law, 29 U.S.C. § 1161 et seq., the Company shall continue to pay the share of the premium for such
coverage that is paid by the Company for active and similarly-situated employees who receive the same type of coverage, during the Consultation Period. The remaining balance of any premium costs, and all premium costs after the Consultation Period,
shall be paid by Dr. Gould on a monthly basis for as long as, and to the extent that, Dr. Gould remains eligible for COBRA continuation. Dr. Gould should consult the COBRA materials to be provided by the Company for details regarding
these benefits. Notwithstanding the foregoing, the Company shall not make any payments to Dr. Gould under this Section 3(c) earlier than the date eight (8) days after Dr. Gould’s timely execution, return and non-revocation
of the Release of Claims. 
 d. Stock Options. Dr. Gould and the Company hereby agree that, notwithstanding any term of any
outstanding stock option held by Dr. Gould as of the date hereof (the “Options”), (i) the Options shall cease vesting no later than February 15, 2016 such that any Options that are not vested as of February 15, 2016
shall be terminated and cancelled as of such date and (ii) Dr. Gould’s right to exercise the Options will terminate three months after the earlier to occur of the date Dr. Gould ceases to be an “Eligible Participant”
(as defined in the Options) and the date of the Company’s 2016 Annual Meeting of Stockholders, provided that in the case of clause (ii) the Options may not be exercised after the Final Exercise Date (as defined in the Options) or at all
if, under the terms of the Options, Dr. Gould’s rights to exercise the Options would have otherwise terminated immediately. 
 e.
Reimbursement of Expenses. The Company shall reimburse Dr. Gould for all reasonable and necessary travel expenses incurred or paid by Dr. Gould in connection with, or related to, the performance of the Services under this Agreement.
Dr. Gould shall submit to the Company itemized monthly statements, in a form satisfactory to the Company, of such expenses incurred in the previous month. The Company shall pay to Dr. Gould amounts shown on each such statement within 30
days after receipt thereof. 
 f. No Additional Consulting Benefits. Dr. Gould agrees that he shall provide the Services in
exchange for the Consulting Benefits described in this Section 3 and that he is not entitled to any benefits, coverages or privileges, including, without limitation, social security, unemployment, medical or pension payments, made available to
employees of the Company or any other consideration or benefits from the Company for the performance of the Services. 

  
 2 

 4. Independent Contractor. It is the express intention of the parties to
this Agreement that Dr. Gould shall be an independent contractor and not an employee, agent, joint venturer or partner of the Company for any purposes whatsoever. 

a. Performance of Services. Dr. Gould shall have the right to control and determine the methods, manner and means of performing
the Services. In performing the Services, the amount of time devoted by Dr. Gould on any given day will be entirely within Dr. Gould’s control, and the Company will rely on Dr. Gould to put in the amount of time as is necessary
to fulfill the requirements of this Agreement. Dr. Gould will provide all equipment and supplies required to perform the Services. 

b. Non-Exclusivity. Dr. Gould retains the right to contract with other companies or entities for his consulting services without
restriction, provided, however, that Dr. Gould remains in compliance with the terms of the Employee Confidentiality and Assignment of Inventions Agreement and the Non-Competition and Non-Solicitation Agreement that he previously executed for
the benefit of the Company and which remain in full force and effect. Likewise, the Company retains a reciprocal right to contract with other companies and/or individuals for consulting services without restriction. 

c. Scope of Authority. Dr. Gould is not authorized to transact business, incur obligations, sell goods, receive payments, solicit
orders or assign or create any obligation of any kind, express or implied, on behalf of the Company or any of the Company’s related or affiliated entities, or to bind in any way whatsoever, or to make any promise, warranty or representation on
behalf of the Company or any of the Company’s related or affiliated entities with respect to any matter, except as expressly authorized in a writing signed by an authorized representative of the Company. Dr. Gould shall not use the
Company’s trade names, trademarks, service names or servicemarks without the prior approval of the Company. 
 5.
Termination. This Agreement may be terminated by either Party prior to September 10, 2016 upon written notice to the other Party. If the Company terminates this Agreement without Cause, Dr. Gould shall continue to receive the
Consulting Benefits described in Section 3 above for the remainder of the original Consultation Period. If the Company terminates this Agreement with Cause, if Dr. Gould terminates this Agreement for any reason or if Dr. Gould
(A) fails to sign the Release of Claims by the close of business on September 10, 2015 or (B) effectively revokes the Release of Claims, the Company shall have no further obligation to pay the Consulting Benefits as of the date that
the Agreement is terminated. For purposes of this Agreement, “Cause” means any of: (a) Dr. Gould’s conviction of, or plea of guilty or nolo contendere to, any crime involving dishonesty or moral turpitude or any felony; or
(b) a good faith finding by the Company that Dr. Gould has (i) engaged in dishonesty, willful misconduct or gross negligence, (ii) breached or threatened to breach the terms of any restrictive covenants or confidentiality
agreement or any similar agreement with the Company, (iii) violated Company policies or procedures, and/or (iv) failed to perform the Services to the Company’s satisfaction, following notice of such failure by the Company and a period
of 15 days to cure. 

  
 3 

 6. Invention, Non-Disclosure, Non-Competition and Non-Solicitation
Obligations. Dr. Gould acknowledges and reaffirms his obligations set forth in the Employee Invention and Non-Disclosure Agreement and the Non-Competition and Non-Solicitation Agreement previously executed for the benefit of the
Company, which obligations shall remain in full force and effect during the Consultation Period as if Dr. Gould were an employee of the Company under such agreements. 

7. Other Agreements. Dr. Gould hereby represents that, except as Dr. Gould has disclosed in writing to the
Company, Dr. Gould is not bound by the terms of any agreement with any third party to refrain from using or disclosing any trade secret or confidential or proprietary information in the course of his consultancy with the Company, to refrain
from competing, directly or indirectly, with the business of such third party or to refrain from soliciting employees, customers or suppliers of such third party. Dr. Gould further represents that his performance of all the terms of this
Agreement and the performance of the Services as a consultant of the Company do not and will not breach any agreement with any third party to which Dr. Gould is a party (including without limitation any nondisclosure or non-competition
agreement), and that Dr. Gould will not disclose to the Company or induce the Company to use any confidential or proprietary information or material belonging to any current or previous employer or others. 

8. Warranties. Dr. Gould will assume sole responsibility for his/her compliance with applicable federal and state
laws and regulations, and shall rely exclusively upon his/her own determination, or that of his/her legal advisers, that the performance of the Services and the receipt of the Consulting Benefits hereunder comply with such laws and regulations.
Dr. Gould acknowledges that he is not relying upon the advice or representation of the Company with respect to the tax treatment of the Consulting Benefits.  

9. Non-Assignability of Contract. This Agreement shall be binding upon, and inure to the benefit of, both parties and their
respective successors and assigns, including any entity with which, or into which, the Company may be merged or which may succeed to its assets or business, provided, however, that the obligations of the Consultant are personal and shall not be
assigned by him. 
 10. Notices. All notices required or permitted under this Agreement shall be in writing and shall
be deemed effective upon personal delivery or upon deposit in the United States Post Office, by registered or certified mail, postage prepaid, addressed to the other party at such address or addresses as either party shall designate to the other.
 
 11. Complete Agreement. Dr. Gould acknowledges that this Agreement, together with the Release of Claims and
the Options, contains the entire understanding between the parties and supersedes, replaces and takes precedence over any prior understanding or oral or written agreement between the parties respecting the subject matter of this Agreement, the
Release of Claims or the Options. Dr. Gould further acknowledges that he is not eligible to receive any payments or benefits under the terms of his offer letter dated April 13, 2013 or the Company’s Executive Severance and Change in
Control Plan. There are no representations, agreements, arrangements, nor understandings, oral or written, between the parties relating to the subject matter of this Agreement that are not fully expressed herein and in the Release of Claims. 

  
 4 

 12. Severability. In the event any provision of this Agreement shall be held
invalid, the same shall not invalidate or otherwise affect in any respect any other term or terms of this Agreement, which term or terms shall remain in full force and effect.  

13. Non-Waiver. No delay or omission by the Company in exercising any right under this Agreement shall operate as a
waiver of that or any other right. A waiver or consent given by the Company on any one occasion shall be effective only in that instance and shall not be construed as a bar to or waiver of any right on any other occasion.  

14. Amendment. This Agreement may be amended or modified only by a written instrument executed by both the Company and
Dr. Gould.  
 15. Counterparts. This Agreement may be executed in two (2) signed counterparts, each
of which shall constitute an original, but all of which taken together shall constitute one and the same instrument.  
 16.
Interpretation. Whenever the context may require, any pronouns used in this Agreement shall include the corresponding masculine, feminine or neuter forms, and the singular forms of nouns and pronouns shall include the plural, and vice
versa. The captions of the sections of this Agreement are for convenience of reference only and in no way define, limit or affect the scope or substance of any section of this Agreement.  

17. Governing Law; Jurisdiction. This Agreement shall be governed by and construed in accordance with the internal laws
of the Commonwealth of Massachusetts without giving effect to any choice or conflict of law provision or rule (whether of the Commonwealth of Massachusetts or any other jurisdiction) that would cause the application of laws of any jurisdictions
other than those of the Commonwealth of Massachusetts.  
 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of
the day and year set forth below. 
  

			
	EPIZYME, INC.
		
	By:	 	 /s/ David Mott

		
	Title:	 	 Director

	
	ROBERT J. GOULD
	
	 /s/ Robert J. Gould

  
 5 

 EXHIBIT A 

RELEASE OF CLAIMS 
 1.
Release of Claims. In exchange for the Consultation Benefits described in Section 3 of the Consulting Agreement, which Dr. Gould acknowledges he would not otherwise be entitled to receive, Dr. Gould hereby fully, forever,
irrevocably and unconditionally releases, remises and discharges the Company, its affiliates, subsidiaries, parent companies, predecessors, and successors, and all of its and their respective past and present officers, directors, stockholders,
partners, members, employees, agents, representatives, plan administrators, attorneys, insurers and fiduciaries (each in their individual and corporate capacities) (collectively, the “Released Parties”) from any and all claims, complaints,
demands, actions, causes of action, suits, rights, debts, sums of money, costs, accounts, reckonings, covenants, contracts, agreements, promises, doings, omissions, damages, executions, obligations, liabilities, and expenses (including
attorneys’ fees and costs), of every kind and nature, whether known or unknown, that Dr. Gould ever had or now has against any or all of the Released Parties, including, but not limited to, any and all claims arising out of or relating to
Dr. Gould’s employment with and/or service as an officer and/or director of the Company or any affiliate, or to Dr. Gould’s separation from employment with the Company or any affiliate, including, but not limited to, all claims
under Title VII of the Civil Rights Act of 1964, 42 U.S.C. § 2000e et seq., the Americans With Disabilities Act of 1990, 42 U.S.C. § 12101 et seq., the Age Discrimination in Employment Act, 29 U.S.C. § 621
et seq., the Genetic Information Nondiscrimination Act of 2008, 42 U.S.C. § 2000ff et seq., the Family and Medical Leave Act, 29 U.S.C. § 2601 et seq., the Worker Adjustment and Retraining
Notification Act (“WARN”), 29 U.S.C. § 2101 et seq., the Rehabilitation Act of 1973, 29 U.S.C. § 701 et seq., the Fair Credit Reporting Act, 15 U.S.C. § 1681 et seq., and the
Employee Retirement Income Security Act of 1974 (“ERISA”), 29 U.S.C. § 1001 et seq., all as amended; all claims arising out of the Massachusetts Fair Employment Practices Act., Mass. Gen. Laws ch. 151B, § 1
et seq., the Massachusetts Civil Rights Act, Mass. Gen. Laws ch. 12, §§ 11H and 11I, the Massachusetts Equal Rights Act, Mass. Gen. Laws. ch. 93, § 102 and Mass. Gen. Laws ch. 214, § 1C, the Massachusetts Labor and
Industries Act, Mass. Gen. Laws ch. 149, § 1 et seq., the Massachusetts Wage Act, Mass. Gen. Laws ch. 149, § 148 et seq. (Massachusetts law regarding payment of wages and overtime), Mass. Gen. Laws ch. 214,
§ 1B (Massachusetts right of privacy law), the Massachusetts Maternity Leave Act, Mass. Gen. Laws ch. 149, § 105D, and the Massachusetts Small Necessities Leave Act, Mass. Gen. Laws ch. 149, § 52D, all as amended; all common law
claims including, but not limited to, actions in defamation, intentional infliction of emotional distress, misrepresentation, fraud, wrongful discharge, and breach of contract; all state and federal whistleblower claims to the maximum extent
permitted by law; all claims to any non-vested ownership interest in the Company, contractual or otherwise; and any claim or damage arising out of Dr. Gould’s employment with and/or separation from the Company (including a claim for
retaliation) under any common law theory or any federal, state or local statute or ordinance not expressly referenced above; provided, however, that nothing in this Agreement prevents Dr. Gould from filing a charge with, cooperating with, or
participating in any proceeding before the Equal Employment Opportunity Commission or a state fair employment practices agency (except that Dr. Gould acknowledges that he may not recover any monetary benefits in connection with any such claim,
charge or proceeding and further waives any rights or claims to any payment, benefit, attorneys’ fees or other remedial relief in connection with any such claim, charge or proceeding). 

  
 6 

 2. Nondisparagement. Dr. Gould understands and agrees that, to the extent
permitted by law, he shall not make any false, disparaging, derogatory or defamatory statements to any person or entity, including, without limitation, any media outlet, industry group, financial institution or current or former employee,
consultant, client or customer of the Company, regarding the Company or any of its respective directors, officers, employees, agents or representatives or about the Company’s business affairs or financial condition; provided, however, that
nothing herein shall be construed as preventing Dr. Gould from making truthful disclosures to any governmental entity or in any litigation or arbitration. 

3. Acknowledgments. Dr. Gould acknowledges that he has been given at least twenty-one (21) days to consider this
Release of Claims and that the Company advised him to consult with an attorney of his own choosing prior to signing. Dr. Gould understands that he may revoke this Release of Claims for a period of seven (7) days after he signs the Release
of Claims by notifying David Mott in writing of such revocation, and this Release of Claims shall not be effective or enforceable until the expiration of the seven (7) day revocation period. Dr. Gould understands and agrees that by
entering into this Release of Claims, he is waiving any and all rights or claims he might have under the Age Discrimination in Employment Act, as amended by the Older Workers Benefit Protection Act, and that he has received consideration beyond that
to which he was previously entitled. 
 4. Business Expenses and Final Compensation. Dr. Gould acknowledges that he has
been reimbursed by the Company for all business expenses incurred in conjunction with the performance of his employment and that no other reimbursements are owed to him. Dr. Gould further acknowledges that he has received payment in full for
all services rendered in conjunction with his employment, including, without limitation, payment for all wages, bonuses, equity, commissions and accrued, unused vacation time, and that no other compensation or consideration is owed to him, including
under the terms of the Company’s Executive Severance and Change in Control Plan, except as explicitly set forth herein and in the Consulting Agreement. 

5. Nature of Agreement. The Parties understand and agree that this Release of Claims is a separation agreement and does not
constitute an admission of liability or wrongdoing on the part of either Party. 
 6. Amendment. This Release of Claims shall
be binding upon the Parties and may not be modified in any manner, except by an instrument in writing of concurrent or subsequent date signed by duly authorized representatives of the Parties hereto. This Release of Claims is binding upon and shall
inure to the benefit of the Parties and their respective agents, assigns, heirs, executors, successors and administrators. 
 7.
Waiver of Rights. No delay or omission by either Party in exercising any right under this Agreement shall operate as a waiver of that or any other right. A waiver or consent given by a Party on any one occasion shall be effective only in
that instance and shall not be construed as a bar to or waiver of any right on any other occasion. 

  
 7 

 8. Validity. Should any provision of this Release of Claims be declared or be
determined by any court of competent jurisdiction to be illegal or invalid, the validity of the remaining parts, terms or provisions shall not be affected thereby and said illegal or invalid part, term or provision shall be deemed not to be a part
of this Release of Claims. 
 9. Voluntary Assent. Dr. Gould affirms that no other promises or agreements of any
kind have been made to or with him by any person or entity whatsoever to cause him to sign this Release of Claims, and that he fully understands the meaning and intent of this Release of Claims. Dr. Gould states and represents that he has had
an opportunity to fully discuss and review the terms of this Release of Claims with an attorney. Dr. Gould further states and represents that he has carefully read this Release of Claims, understands the contents herein, freely and voluntarily
assents to all of the terms and conditions hereof, and signs his name of his own free act. 
 10. Applicable Law. This
Release of Claims shall be governed by the laws of the Commonwealth of Massachusetts without regard to conflict of laws provisions. The Parties hereby irrevocably submit to and acknowledge and recognize the jurisdiction of the courts of the
Commonwealth of Massachusetts, or if appropriate, a federal court located in the Commonwealth of Massachusetts (which courts, for purposes of this Release of Claims, are the only courts of competent jurisdiction), over any suit, action or other
proceeding arising out of, under or in connection with this Release of Claims or the subject matter hereof. 
 11. Entire
Agreement. This Release of Claims, along with the Consulting Agreement, contains and constitutes the entire understanding and agreement between the Parties hereto with respect to Dr. Gould’s separation and the settlement of claims
against the Company and cancels all previous oral and written negotiations, agreements, commitments and writings in connection therewith.  

12. Counterparts. This Release of Claims may be executed in any number of counterparts, each of which when so executed and
delivered shall be taken to be an original, but all of which together shall constitute one and the same document. Facsimile and PDF signatures shall be deemed to be of equal force and effect as originals. 

  
 8 

 IN WITNESS WHEREOF, the Parties, intending to be legally bound, have executed this Release of Claims on
the date(s) indicated below.  
  

					
	EPIZYME, INC.	 		  	
			
	  
	 		  	  

	David Mott	 		  	Date
	Director	 		  	

 TO BE SIGNED ON, BUT NOT BEFORE, SEPTEMBER 10, 2015. 

I hereby agree to the terms and conditions set forth above. I have been given at least twenty-one (21) days to consider this Release of Claims and I
have chosen to execute this on the date below. I intend that this Release of Claims will become a binding agreement between me and the Company if I do not revoke my acceptance in writing to David Mott within seven (7) days. 

 

					
	  
	  		  	  

	Robert J. Gould	  		  	Date

  
 9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00248-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00248-of-00352.parquet"}]]